phenoxymethyl penicillin
Phase 2Small molecule
phenoxymethyl penicillin is one of 7 small molecule programs targeting Rheumatic Heart Disease. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Rheumatic Heart Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Xarelto
WWim Janssens
Approved
Cysteine Hydrochloride
NovartisPhase 2
Rituxan
RochePhase 2
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
phenoxymethyl penicillin
IImperial College London
Phase 2
Thymosin Alpha1
SSun Yat-sen University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rheumatic Heart Disease1 trial
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A Non-inferiority Randomized Trial
Active, not recruiting·CChildren's Hospital Medical Center, Cincinnati·Phase 2·NCT05693545·1,004 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for phenoxymethyl penicillin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImperial College London